EUVIMEDEUVIMED entdecken
Multizentrische Studie

Clinical outcomes for 2788 patients with transthyretin amyloidosis: Tafamidis meglumine early access program in France

Olivier Lairez, Patricia Réant, Jocelyn Inamo, Julien Jeanneteau, Fabrice Bauer, Gilbert Habib, Jean-Christophe Eicher, Benoit Lequeux, Damien Legallois, Constant Josse, Aurelie Hippocrate, Mathilde Bartoli und 8 weitere

Archives of Cardiovascular Diseases · 2025-02 · 118 (2) · 123-132

DOI: 10.1016/j.acvd.2024.08.006 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Archives of Cardiovascular Diseases, 2025-02. Verfasst von Olivier Lairez und 19 weiteren Autor:innen. Beteiligte Einrichtung: Cardiac Imaging Centre, Department of Cardiology, Toulouse University Hospital, 31059 Toulouse, France. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Benzoxazoles, Cardiomyopathies. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Early access experience in France with tafamidis meglumine, a selective transthyretin stabilizer for transthyretin-related amyloidosis cardiomyopathy (ATTR-CM), following transthyretin-related amyloidosis (ATTR) polyneuropathy approval and positive ATTR-ACT study results. AIM: To describe the characteristics and clinical outcomes for patients in the French ATTR-CM tafamidis meglumine early access programme (28 Nov 2018 to 01 Jun 2021). METHODS: Patients with confirmed ATTR-CM received tafamidis meglumine 20mg/day or 80mg/day. Demographic and clinical data were collected prospectively until patients discontinued treatment or died, or the programme ended. RESULTS: Overall, 222 physicians from 126 centres enrolled 2788 patients. The median age was 82years, 81.6% were male and New York Heart Association severity was class I for 12.8%, class II for 60.1% and class III for 27.0%. Overall, 1943 (74.6%) had genetic testing, and the results were available at tafamidis start for 1208 (62.2%) patients: 995 (82.4%) had wild-type ATTR and 213 (17.6%) had hereditary ATTR. Most patients started treatment≤12months after diagnosis (88.3%): 2268 (81.3%) at 20mg/day, with 401 (17.7%) increasing to 80mg/day. Median follow-up duration was 11.8months. New York Heart Association class improved or remained stable for 1299 (77.6%), whereas 376 (22.4%) worsened between inclusion and last follow-up. Among patients initiated at 80mg, 297 (81.1%) improved or remained stable and 69 (18.9%) worsened. New York Heart Association class progression did not vary with age. The 18-month survival rates were 89.8% (95% confidence interval: 87.0-92.0) among patients aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialBenzoxazolesCardiomyopathiesHumansMaleFemaleFranceAgedTreatment OutcomeAged, 80 and overTime FactorsMiddle AgedProspective Studies

Stichwörter der Autor:innen

FranceHeart failureReal-world dataTafamidisTransthyretin cardiac amyloidosis

Substanzen

Benzoxazolestafamidis

Autor:innen und Institutionen

  • Cardiac Imaging Centre, Department of Cardiology, Toulouse University Hospital, 31059 Toulouse, France.
  • Cardiology Department, Haut-Levêque Hospital, Bordeaux University Hospital, University of Bordeaux, Inserm 1045, IHU Lyric, CIC1401, 33600 Pessac, France.
  • Reception Team 7525, Cardiology Department, Hospital P. Zobda-Quitman, Martinique University Hospital, University of Antilles, 97261 Fort-de-France, Martinique.
  • Cardiology, Clinique Saint-Joseph, 49800 Trelazé, France.
  • Department of Cardiac Surgery, Rouen University Hospital, Normandy University, UNIROUEN, Inserm U1096, 76000 Rouen, France.
  • Cardiology Department, La Timone University Hospital, 13005 Marseille, France.

Zitieren

APA

Lairez, O., Réant, P., Inamo, J., Jeanneteau, J., Bauer, F., Habib, G., Eicher, J. C., Lequeux, B., Legallois, D., Josse, C., Hippocrate, A., Bartoli, M., Dubois, M., Noirot Cosson, C., Squara, P. A., Fievez, S., Quinault, A., Rudant, J., Kharoubi, M., & Damy, T. (2025). Clinical outcomes for 2788 patients with transthyretin amyloidosis: Tafamidis meglumine early access program in France. Archives of Cardiovascular Diseases, 118(2), 123-132. https://doi.org/10.1016/j.acvd.2024.08.006

Vancouver

Lairez O, Réant P, Inamo J, Jeanneteau J, Bauer F, Habib G, et al. Clinical outcomes for 2788 patients with transthyretin amyloidosis: Tafamidis meglumine early access program in France. Archives of Cardiovascular Diseases. 2025;118(2):123-132. doi:10.1016/j.acvd.2024.08.006

BibTeX
@article{Lairez2025,
  author = {Lairez, Olivier and Réant, Patricia and Inamo, Jocelyn and Jeanneteau, Julien and Bauer, Fabrice and Habib, Gilbert and Eicher, Jean-Christophe and Lequeux, Benoit and Legallois, Damien and Josse, Constant and Hippocrate, Aurelie and Bartoli, Mathilde and Dubois, Margaux and Noirot Cosson, Charlotte and Squara, Pierre-Alexandre and Fievez, Stephane and Quinault, Aurore and Rudant, Jeremie and Kharoubi, Mounira and Damy, Thibaud},
  title = {Clinical outcomes for 2788 patients with transthyretin amyloidosis: Tafamidis meglumine early access program in France},
  journal = {Archives of Cardiovascular Diseases},
  year = {2025},
  volume = {118},
  number = {2},
  pages = {123--132},
  doi = {10.1016/j.acvd.2024.08.006}
}
Kostenlos starten →